# A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer

> **NCT06218667** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Degarelix
- **PROCEDURE:** Radical Prostatectomy

## Key facts

- **NCT ID:** NCT06218667
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-11
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study drug not available per sponsor
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06218667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06218667, "A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06218667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*